InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,712.69
(
-0.28%
)
US TECH 100
19,440.40
(
0.00%
)
Dow Jones
41,794.60
(
-0.61%
)
Brent Oil
75.07
(
-0.07%
)
Bitcoin
68,843.34
(
1.51%
)
Post# of 253527
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: DewDiligence post# 211314

Monday, 05/15/2017 6:15:53 PM

Monday, May 15, 2017 6:15:53 PM

Post# of 253527
FGEN management has been pretty clear that they expect their drug to be outside the bundle because it is not the oral equivalent of an ESA. To my knowledge, that's the standard based on the way the regulations are written right now.

That said, obviously Fresenius in any event now has an incentive to prefer the AKBA drug once it is approved.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up